These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39212430)

  • 21. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
    Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
    J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Down-Selection of Repurposed Drug Candidates for COVID-19.
    MacRaild CA; Mohammed MU; Faheem ; Murugesan S; Styles IK; Peterson AL; Kirkpatrick CMJ; Cooper MA; Palombo EA; Simpson MM; Jain HA; Agarwal V; McAuley AJ; Kumar A; Creek DJ; Trevaskis NL; Vasan SS
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system.
    Punekar M; Kshirsagar M; Tellapragada C; Patil K
    Microb Pathog; 2022 Jul; 168():105608. PubMed ID: 35654381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network medicine framework for identifying drug-repurposing opportunities for COVID-19.
    Morselli Gysi D; do Valle Í; Zitnik M; Ameli A; Gan X; Varol O; Ghiassian SD; Patten JJ; Davey RA; Loscalzo J; Barabási AL
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33906951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19.
    Aldea M; Michot JM; Danlos FX; Ribas A; Soria JC
    Cancer Discov; 2021 Jun; 11(6):1336-1344. PubMed ID: 33846172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.
    Yadav M; Dhagat S; Eswari JS
    Eur J Pharm Sci; 2020 Dec; 155():105522. PubMed ID: 32827661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
    Mousavi SZ; Rahmanian M; Sami A
    Infect Genet Evol; 2020 Dec; 86():104610. PubMed ID: 33130005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
    Cava C; Bertoli G; Castiglioni I
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients.
    Wang H; Zhang J; Lu Z; Dai W; Ma C; Xiang Y; Zhang Y
    Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34505138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.
    Prasad K; Khatoon F; Rashid S; Ali N; AlAsmari AF; Ahmed MZ; Alqahtani AS; Alqahtani MS; Kumar V
    Int J Biol Macromol; 2020 Nov; 163():1-8. PubMed ID: 32599245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19.
    Mirmohammadi S; Kianmehr A; Sabbaghian A; Mohebbi A; Shahbazmohammadi H; Sheykharabi M; Bazzi Z
    Infect Genet Evol; 2022 Sep; 103():105318. PubMed ID: 35718334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
    Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
    Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug repurposing: identification of SARS-CoV-2 potential inhibitors by virtual screening and pharmacokinetics strategies.
    Rashid Z; Fatima A; Khan A; Matthew J; Yousaf MZ; Nadeem N; Hasan TN; Rehman MU; Naqvi SS; Khan SJ
    J Infect Dev Ctries; 2024 Apr; 18(4):520-531. PubMed ID: 38728643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
    Mosharaf MP; Reza MS; Kibria MK; Ahmed FF; Kabir MH; Hasan S; Mollah MNH
    Sci Rep; 2022 Mar; 12(1):4279. PubMed ID: 35277538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
    Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
    Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
    Front Immunol; 2021; 12():789317. PubMed ID: 34975885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.